Nikita Wadhwani1, Hooper R Markert1, Raoud Marayati1, Laura V Bownes1, Colin H Quinn1, Jamie M Aye2, Jerry E Stewart1, Karina J Yoon3, Elizabeth A Beierle4. 1. Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave. South, Lowder, Room 300, Birmingham, AL 35233, USA. 2. Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, AL 35233, USA. 3. Department of Pharmacology and Toxicology, University of Alabama at Birmingham, AL 35233, USA. 4. Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave. South, Lowder, Room 300, Birmingham, AL 35233, USA. Electronic address: elizabeth.beierle@childrensal.org.
Abstract
BACKGROUND: Novel therapies are needed for patients with hepatoblastoma because of an increasing incidence of disease and poor prognosis for advanced, refractory, and recurrent disease. PIM kinases promote tumorigenesis in hepatoblastoma. A novel PIM inhibitor, PIM447, has shown promise in inhibiting oncogenesis in hematologic and lymphoid malignancies. We hypothesized that PIM inhibition with PIM447 would result in decreased tumorigenesis in hepatoblastoma. METHODS: The effects of PIM447 on hepatoblastoma viability, proliferation, motility, apoptosis, and tumor cell stemness were assessed in HuH6, a human hepatoblastoma cell line, and COA67, a human hepatoblastoma patient-derived xenograft. RESULTS: PIM447 significantly decreased the viability, proliferation, and motility of HuH6 and COA67 cells. Apoptosis significantly increased following PIM447 treatment. PIM447 had a significant impact on tumor cell stemness as evidenced by decreased expression of CD133 and reduced ability of HuH6 and COA67 cells to form tumorspheres. Furthermore, combining PIM447 with cisplatin resulted in a significant decrease in cell viability compared to either treatment alone. CONCLUSION: We showed that PIM447 inhibits oncogenesis and potentiates the effects of cisplatin in hepatoblastoma and, therefore, warrants further investigation as a potential therapeutic agent for hepatoblastoma.
BACKGROUND: Novel therapies are needed for patients with hepatoblastoma because of an increasing incidence of disease and poor prognosis for advanced, refractory, and recurrent disease. PIM kinases promote tumorigenesis in hepatoblastoma. A novel PIM inhibitor, PIM447, has shown promise in inhibiting oncogenesis in hematologic and lymphoid malignancies. We hypothesized that PIM inhibition with PIM447 would result in decreased tumorigenesis in hepatoblastoma. METHODS: The effects of PIM447 on hepatoblastoma viability, proliferation, motility, apoptosis, and tumor cell stemness were assessed in HuH6, a human hepatoblastoma cell line, and COA67, a human hepatoblastoma patient-derived xenograft. RESULTS: PIM447 significantly decreased the viability, proliferation, and motility of HuH6 and COA67 cells. Apoptosis significantly increased following PIM447 treatment. PIM447 had a significant impact on tumor cell stemness as evidenced by decreased expression of CD133 and reduced ability of HuH6 and COA67 cells to form tumorspheres. Furthermore, combining PIM447 with cisplatin resulted in a significant decrease in cell viability compared to either treatment alone. CONCLUSION: We showed that PIM447 inhibits oncogenesis and potentiates the effects of cisplatin in hepatoblastoma and, therefore, warrants further investigation as a potential therapeutic agent for hepatoblastoma.
Authors: Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen Journal: FEBS Lett Date: 2004-07-30 Impact factor: 4.124
Authors: Laura L Stafman; Mary G Waldrop; Adele P Williams; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle Journal: J Pediatr Surg Date: 2019-02-28 Impact factor: 2.545
Authors: Bassan J Allan; Punam P Parikh; Sofia Diaz; Eduardo A Perez; Holly L Neville; Juan E Sola Journal: HPB (Oxford) Date: 2013-04-22 Impact factor: 3.647
Authors: Marc S Raab; Sheeba K Thomas; Enrique M Ocio; Andreas Guenther; Yeow-Tee Goh; Moshe Talpaz; Nicolas Hohmann; Sylvia Zhao; Fang Xiang; Carl Simon; K Gary Vanasse; Shaji K Kumar Journal: Leukemia Date: 2019-05-15 Impact factor: 11.528
Authors: Laura L Stafman; Adele P Williams; Evan F Garner; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle Journal: Transl Oncol Date: 2018-11-06 Impact factor: 4.243
Authors: Rishi Raj Rikhi; Kimberlee K Spady; Ruth I Hoffman; Michael S Bateman; Max Bateman; Lisa Easom Howard Journal: Front Pediatr Date: 2016-03-21 Impact factor: 3.418